Table 1.

Patient characteristics, treatment, outcomes, and karyotype changes

Patient	Age,Sex	Diagnosis karyotypea	FLT3 status at diagnosis	Therapy	RFS, OSb	Subsequent karyotype	AML status when new karyotype emerged	FLT3 status when new karyotype emerged
1	53, F	46,XX	ITD	AraC, Ida: HIDAC, topotecan: sorafenib; alloSCT	163, 197	46,XX,t(1;5) (q25;q13)[5]/46,XX[15]	Relapse 1	ITD and D835
2	56, F	46,XX	ITD	AraC, DNR; HIDAC	408, 966	46,XX,t(2;4) (p24;q13)[5]/46,XX,del(16) (q12)[2]/dup(1) (q21q32)[1]/46, XX[12] nucish(1p32×2) (1q21×3)[38/200]	CR2; Relapse 2	ITD
3	74, F	46,XX	ITD	AraC, Ida, sorafenib; HIDAC	183, 394	46,XX,t(4;4) (q21;q35)[7]/46,XX[13]	Relapse 1. after chemotherapy	ITD
4	58, F	46,XX	ITD	AraC, Ida: HIDAC	783, 989	46,XX,t(5;13) (q31;q12)[20]	Relapse 1	ITD
5	64, M	46,XY	ITD	AraC, Ida: HIDAC	229, 434	46,XY,t(9;22) (q34:q11.2)[4]/46,XY[8]	Relapse 1, after chemotherapy	ITD
6	48, M	46,XY	ITD	AraC, DNR. VP16; alloSCT	227, 243	46,XY,inv(10) (p11.2q21.2)[12]/46,XY[8]	Relapse 1	ITD
7	64, M	46,XY	ITD	AraC, Ida, sorafenib; alloSCT	177, 726+	46,XY,t(10;13) (p11.1q11)[9]/46,XY[9]// 46,XX[2]	Relapse 1	ITD
8	53, F	46,XX	ITD	AraC, DNR. VP16; vorinostat, AraC, VP16; alloSCT	330, 435	46,X,t(X;10) (q13;q24),t(3;14) (p21;q11.2), t( 12:17) (p12;q12) [15]//46,XY[5]	Relapse 1	ITD
9	43, F	46,XX	ITD	AraC, DNR. VP16; HIDAC	179, 413	46,XX,der(2)t(2;?) (q21;?),del(3) (q12), der(6)t(6;?) (p22;?), der(7)t(7;?) (p15;?), ?del(11) (p12p15), −17,−22,−2mar(19]/46,XX[1]	Relapse 1	ITD
10	49, F	46,XX	ITD	AraC, Ida; HIDAC	175, 567+	49,XX,+6,+8, +13[2]/46,XX[18]	Relapse 1	ITD

Abbreviations: M, male; F, female; AraC, cytarabine; Ida, idarubicin; DNR, daunorubidn; VP16, etoposide; HIDAC, high dose cytarabine

^a20 metaphases.

^bDays.